HMN Financial Inc
Change company Symbol lookup
Select an option...
HMNF HMN Financial Inc
BAM Brookfield Asset Management Inc
XOM Exxon Mobil Corp
NEWR New Relic Inc
T AT&T Inc
AICAF Air China Ltd
JNJ Johnson & Johnson
TIP iShares TIPS Bond ETF
OCUL Ocular Therapeutix Inc

Financials : Thrifts & Mortgage Finance | Small Cap Value
Company profile

HMN Financial, Inc. (HMN) is a stock savings bank holding company that owns Home Federal Savings Bank (the Bank). The Bank operates retail banking and loan production facilities in Minnesota, Iowa and Wisconsin. The Bank has two subsidiaries, Osterud Insurance Agency, Inc., which offers financial planning products and services, and HFSB Property Holdings, LLC, which acts as an intermediary for the Bank in holding and operating certain foreclosed properties. HMN's business involves attracting deposits from the general public and businesses and using such deposits to originate or purchase one- to four-family residential, commercial real estate and multi-family mortgage loans, among others. HMN invests in mortgage-backed and related securities, the United States government agency obligations and other permissible investments. HMN serves the southern Minnesota counties of Dodge, Fillmore, Freeborn, Houston, Mower, Olmsted and Winona, and portions of Steele, Goodhue and Wabasha.

Closing Price
Day's Change
0.10 (0.75%)
B/A Size
Day's High
Day's Low
(Heavy Day)

10-day average volume:

NBE-Therapeutics Appoints Bertrand Damour as Chief Executive Officer

9:39 am ET August 3, 2020 (PR Newswire) Print

NBE-Therapeutics, the Swiss-based company developing best in class cancer therapies based on its proprietary, highly differentiated Antibody Drug Conjugate (ADC) platform, announces the appointment of Bertrand Damour as Chief Executive Officer.

Bertrand Damour has 20 years' management experience in the biotech industry in Europe and US as CEO of biotech companies and in the banking industry. He was previously CEO of: US proteomics company GeneProt Inc.; Mind NRG, a Swiss biotech in the field of CNS (which was acquired by Minerva Neurosciences); OncoEthix, a Swiss based oncology company in the field of epigenetics, (which was acquired by Merck & Co. for US$375 million); and more recently at Synthena AG, a company developing Oligonucleotide based therapeutics for the treatment of genetic neuro muscular diseases. Bertrand has extensive expertise in corporate transactions, including M&A, LBOs and IPOs gained while working in the banking industry at J.P. Morgan, Rabobank International and Deutsche Bank in New York and London.

Detlev Mennerich, Partner at Boehringer Ingelheim Ventures and Board Member of NBE-Therapeutics, commented: "We are delighted to welcome Bertrand to NBE-Therapeutics. His extensive financial, management, and biotech expertise will be invaluable as we take NBE-Therapeutics to the next stage of development and help maximize the potential of its unique ADC platform."

Bertrand Damour, the new CEO of NBE-Therapeutics, said: "I am very enthusiastic about my new role with NBE-Therapeutics. The company has a fantastic technology platform and I have been genuinely impressed by the management's professionalism and the unsurpassed track record of the scientific team. NBE-Therapeutics has an exciting future and I am proud to be a part of the team to help drive our success."

Dr. Ulf Grawunder, founder and previous CEO of the company will move to a new role as Chief Operating Officer and Chief Development Officer. He will be focused on moving the company's first drug candidate, NBE-002, an anti-ROR1 ADC, through clinical development.

Commenting on the appointment, Dr. Ulf Grawunder, Founder of NBE-Therapeutics, said; "I am very pleased to have Bertrand take over as CEO with his vast expertise in corporate transactions. I am looking forward to working with him at this very exciting stage of the company."

NBE-Therapeutics' best in class iADC(TM) platform creates highly potent and safe immune-stimulatory ADCs with an anthracycline payload, inducing a long-lasting immunological anti-tumor effect. Lead candidate NBE-002 has shown unprecedented preclinical efficacy, as well as favorable safety profile in multiple pipeline programs. A first-in-human study with NBE-002 is expected to commence in 2020, focusing on triple negative breast cancer and lung cancer, as well as other solid cancer indications and lymphomas.

About NBE-Therapeutics

NBE-Therapeutics is a privately-owned Swiss biotech company based in Basel and founded in 2012 with the vision of developing next-generation immune-stimulatory antibody drug conjugate (iADC(TM)) products. NBE advances its products to clinical proof of concept with the goal of improving treatment options for cancer patients.

The company leverages proprietary platforms covering all aspects of ADC development: its Transpo-mAb Display(TM) technology for antibody discovery, its SMAC-Technology(TM) for site-specific payload conjugation of toxins to antibodies and a novel highly effective and immune-stimulatory anthracycline-based toxin platform. The company is financially backed by the Boehringer Ingelheim Venture Fund (D), the PPF Group and Novo Holdings (DK) as institutional investors, and by additional Swiss, German and Dutch private investors. For more information about NBE visit the website

A photo of Bertrand Damour is available on request.

View original content:

SOURCE NBE-Therapeutics

comtex tracking

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.